Physician profile
Kellie Aarons
NPI 1558865477
$1,240.74
in general payments reported to CMS, 2019-2025
21 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.54 · 2021: $86.36 · 2022: $176 · 2023: $396 · 2024: $415 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $253.56 | 2024-2025 | Inspire |
| Novo Nordisk INC | $117.64 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $111.02 | 2021-2023 | |
| Lilly USA, LLC | $110.53 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $98.19 | 2022-2024 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $69.65 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Alexion Pharmaceuticals, INC. | $63.15 | 2023 | Ultomiris |
| Astrazeneca Pharmaceuticals Lp | $50.57 | 2021-2023 | Breztri |
| Welch Allyn | $43.67 | 2021 | |
| Abbott Laboratories | $42.41 | 2023-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $41.06 | 2024 | Rexulti, Nuedexta |
| Pfizer INC. | $37.19 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $36.40 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $29.50 | 2022 | |
| Exact Sciences Corporation | $29.20 | 2023 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $20.19 | 2023 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $19.34 | 2019 | |
| Dexcom, INC. | $18.56 | 2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $16.96 | 2023 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.60 | 2024 | |
| Abbvie INC. | $15.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Aarons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.